Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

NCT07631325 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Cutaneous Melanoma

Interventions

DRUG: Axelopran
DRUG: Nivolumab

Sponsor

John Kirkwood

Collaborators

[object Object]